June 07, 2012 -- In response to an increased demand, Recipharm invests in additional cartridge filling machine for injectable solutions. The investment of € 600.000 will strengthen Recipharm’s position in cartridge filling for injectables by offering a high quality and competitive solution to clients.
7th June 2012 - Recipharm, the international pharmaceutical contract development and manufacturing organization, today announced that it has invested in a brand new state of the art Dara cartridge filling machine at its modern facility in Monts (Loire Valley, France).
The machine is fully validated and producing commercial batches under aseptic conditions. Filling volumes between 1.5 ml and 5 ml can be accommodated at speeds up to 7200 cartridges per hour. The integrated design has been optimised for precise conveying of cartridges as well as gas flushing during filling/closing and crimping without particulate release.
General Manager of Recipharm Monts, Michel Saudemon commented “Whilst we have for many years filled cartridges in Monts, this new machine allows us to offer a wider client base access to this capability. This should not only reduce lead times but also increase reliability and flexibility. It also complements very well the vial filling activity which we perform here too. Our well developed technology transfer and project management processes are clearly a key component of the offering and it is allowing us to deliver a high quality service to clients both new and old. We are also just about to undertake a mock FDA inspection in preparation for products which are being registered in the US. This is a very exciting time for Monts and we are very pleased about this latest investment”.
Recipharm AB is a leading contract development and manufacturing organization (CDMO) based in Sweden employing some 1700 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers. For more information visit; www.recipharm.com
Recipharm – Nathalie Robineau-Romanet, Tel : + 33 247 211 010, Nathalie.Romanet-Robineau@recipharm.com
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on:
E-mail: firstname.lastname@example.org or email@example.com
Tel: +44 (0) 207 861 3019/3043